Stock Fundamentals

AI Research Report

Generate a comprehensive financial analysis report powered by AI

NGNE.US - Current Price

$16.59

Company Information

▼
Company Name
Neurogene Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US64135M1053
CIK: 0001404644
CUSIP: 64135M105
Currency: USD
Full Time Employees: 107
Phone: 855 508 3568
Website: https://www.neurogene.com
Fiscal Year End: December
IPO Date: Mar 07, 2014
Description:

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.

Address:

535 W 24th Street, New York, NY, United States, 10011

Directors & Officers

▼
Name Title Year Born
Dr. Rachel L. McMinn Ph.D. Founder, Executive Chair & CEO 1973
Ms. Christine Mikail Cvijic J.D. President & CFO 1978
Dr. Julie Jordan M.D. Chief Medical Officer 1972
Mr. Arvind Sreedharan Senior Vice President of Business Operations NA
Dr. Stuart Cobb Ph.D. Chief Scientific Officer 1970
Ms. Donna M. Cochener-Metcalfe J.D. Senior VP, General Counsel & Corporate Secretary 1975
Dr. Effie Albanis M.D. Senior Vice President of Clinical Affairs NA
Dr. Andrew E. Mulberg CPI, FAAP, M.D. Senior Vice President of Regulatory Affairs, Quality Assurance & Quality Control NA
Mr. Ricardo Jimenez Senior Vice President of Technical Operations NA

Shares Statistics

▼
Shares Outstanding: 15.49M
Shares Float: 5.21M
% Insiders: 854.40%
% Institutions: 10,478.60%
Short % Float: 28.10%

Valuation Metrics

▼
Enterprise Value: $13.53M
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

▼
Market Cap: $267.66M
EBITDA: $-94.21M
Book Value: $17.97
Earnings/Share: $-4.10
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -26.91%
ROE (TTM): -42.25%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Stock Price History

▼

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

▼

Revenue & Net Income

Operating Expenses

Balance Sheet Overview

Earnings Per Share (EPS)

Earnings History

▼
Date EPS Actual EPS Estimate Difference Surprise %
Sep 30, 2025 -0.99 -1.18 N/A 1,610.17%
Jun 30, 2025 -1.05 -1.11 N/A 540.54%
Mar 31, 2025 -1.08 -1.12 N/A 357.14%
Dec 31, 2024 -0.99 -1.13 N/A 1,225.74%
Sep 30, 2024 -1.19 -1.22 N/A 225.41%
Jun 30, 2024 -1.09 -1.05 N/A -380.95%
Mar 31, 2024 -1.00 -1.13 N/A 1,150.44%
Dec 31, 2023 -1.51 -1.17 N/A -2,905.98%
Sep 30, 2023 -0.41 -0.03 N/A -125,900.00%
Jun 30, 2023 -0.04 -0.04 N/A 0.00%
Mar 31, 2023 -0.26 -0.22 N/A -1,818.18%
Dec 31, 2022 -0.24 -0.19 N/A -2,631.58%
Sep 30, 2022 -0.24 -0.30 N/A 2,113.05%
Jun 30, 2022 -0.28 -0.30 N/A 666.67%
Mar 31, 2022 -0.28 -0.30 N/A 604.03%
Dec 31, 2021 -0.28 -0.30 N/A 530.94%
Sep 30, 2021 -0.28 -0.28 N/A -61.09%
Jun 30, 2021 -0.27 -0.26 N/A -305.34%
Mar 31, 2021 -0.27 -0.23 N/A -1,842.11%
Dec 31, 2020 -0.22 -0.24 N/A 994.68%
Sep 30, 2020 -0.04 -0.22 N/A 8,181.82%
Jun 30, 2020 -0.20 -0.21 N/A 476.19%
Mar 31, 2020 -0.18 -0.23 N/A 2,173.91%
Dec 31, 2019 -0.23 -0.28 N/A 1,785.71%
Sep 30, 2019 -2.26 -0.04 N/A -555,000.00%
Jun 30, 2019 -0.09 -0.05 N/A -8,000.00%
Mar 31, 2019 -0.09 -0.23 N/A 6,086.96%
Dec 31, 2018 -0.21 -0.79 N/A 7,341.77%
Sep 30, 2018 -0.64 -0.21 N/A -20,476.19%
Jun 30, 2018 0.12 -0.59 N/A 12,033.90%
Mar 31, 2018 -0.62 -0.66 N/A 606.06%
Dec 31, 2017 -0.69 -0.57 N/A -2,105.26%
Sep 30, 2017 -0.50 -0.59 N/A 1,525.42%
Jun 30, 2017 -0.59 -0.51 N/A -1,568.63%
Mar 31, 2017 -0.36 -0.51 N/A 2,941.18%
Dec 31, 2016 -0.48 -0.51 N/A 588.24%
Sep 30, 2016 -0.46 -0.58 N/A 2,068.97%
Jun 30, 2016 -0.63 -0.41 N/A -5,365.85%
Mar 31, 2016 -0.63 -0.35 N/A -8,000.00%
Dec 31, 2015 -0.39 -0.37 N/A -540.54%
Sep 30, 2015 -0.26 -0.45 N/A 4,222.22%
Jun 30, 2015 -0.43 -0.56 N/A 2,321.43%
Mar 31, 2015 -0.44 -0.81 N/A 4,567.90%
Dec 31, 2014 -0.60 -0.76 N/A 2,105.26%
Sep 30, 2014 -0.78 -0.45 N/A -7,333.33%
Jun 30, 2014 -0.51 N/A N/A N/A
Mar 31, 2014 -1.28 N/A N/A N/A

Balance Sheet (Yearly)

▼
Date Cash Total Debt Total Assets Total Liabilities Total Equity
2024-12-31 $136.59M $N/A $335.73M $25.36M $310.38M
2023-12-31 $148.21M $N/A $222.57M $36.55M $186.02M
2022-12-31 $82.02M $N/A $109.27M $10.64M $98.63M
2021-12-31 $70.54M $N/A $101.49M $193.36M $-91.88M
2020-12-31 $192.56M $N/A $210.52M $19.30M $191.22M
2019-12-31 $143.09M $N/A $147.02M $5.34M $141.69M
2018-12-31 $76.93M $N/A $77.62M $4.95M $72.67M
2017-12-31 $52.03M $N/A $110.33M $11.44M $98.89M
2016-12-31 $32.30M $N/A $154.38M $9.72M $144.66M
2015-12-31 $39.53M $N/A $113.34M $4.92M $108.42M
2014-12-31 $14.91M $N/A $41.42M $5.28M $36.15M
2013-12-31 $54.13M $N/A $58.77M $7.48M $51.28M
2012-12-31 $2.00M $N/A $2.34M $1.47M $874.03K
2011-12-31 $9.24M $N/A $9.88M $1.30M $8.59M

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
May 14, 2025 N/A N/A N/A N/A N/A N/A
Mar 13, 2025 N/A N/A N/A N/A N/A N/A
Nov 26, 2024 N/A N/A N/A N/A N/A N/A
Nov 22, 2024 N/A N/A N/A N/A N/A N/A
Nov 22, 2024 N/A N/A N/A N/A N/A N/A

Watchlist

0

No stocks in watchlist